RTW Fund Group GP, LLC and its Managing Member Roderick Wong filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing a combined 9.9% interest in Yarrow Bioscience, Inc. as of September 30, 2026.

Key Highlights

  • Reporting persons: RTW Fund Group GP, LLC (a Delaware limited liability company) and Roderick Wong, M.D., its Managing Member, filed jointly as Amendment No. 1.
  • Beneficial ownership: Each reporting person is listed as beneficially owning 1,145,149 shares of Yarrow Bioscience common stock, par value $0.0001 per share.
  • Ownership percentage: The filing states each reporting person holds 9.9% of the class as of September 30, 2026, based on warrant exercise limits capped at 9.99% of outstanding shares.
  • Voting and dispositive power: Both reporting persons report zero sole voting or dispositive power; all 1,145,149 shares are held under shared voting and shared dispositive power.
  • Warrant cap: According to the filing, the Warrants cannot be exercised to the extent the reporting persons would beneficially own more than 9.99% of outstanding shares after any such exercise.
  • Issuer formerly known as: The filing identifies Yarrow Bioscience, Inc. as "formerly known as VYNE Therapeutics, Inc."

RTW Fund Group and Roderick Wong Disclose Shared Position in Yarrow Bioscience via Warrants

According to the filing, RTW Fund Group GP, LLC serves as the manager of a certain entity referred to as the "RTW Entity," which directly holds the shares reported. Roderick Wong, M.D., as Managing Member of RTW Fund Group, is a co-reporting person with respect to the same shares. The filing identifies Yarrow Bioscience, Inc., listed on NASDAQ:YARW, as a bioscience company formerly operating under the name VYNE Therapeutics, Inc., with principal executive offices at 470 James Street, Suite 007, New Haven, CT 06513. The business address for both reporting persons is listed as 40 10th Avenue, Floor 7, New York, New York 10014.

The filing states that the 1,145,149 shares reported as beneficially owned are calculated as of September 30, 2026 and "assume the exercise of warrants held by the Reporting Persons to the maximum extent permissible in accordance with their terms." Because the Warrants contain a provision preventing exercise beyond the 9.99% ownership threshold, the reported figure reflects that ceiling. The filing notes that "the RTW Entity has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein." Neither reporting person claims sole voting or dispositive authority; all shared powers are attributed to 1,145,149 shares in each case.

The statement also includes a certification that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." This amendment follows an initial Schedule 13G filed by the same reporting persons on July 30, 2026, with the Joint Filing Agreement incorporated by reference to that earlier filing.

What Was Disclosed

RTW Fund Group GP, LLC and Roderick Wong, M.D. disclosed an aggregate beneficial ownership of 1,145,149 shares, representing 9.9% of Yarrow Bioscience common stock as of September 30, 2026, held entirely through shared voting and shared dispositive power tied to warrants with a 9.99% exercise cap.